Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
4(100.0%)
4Total
Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05551793Phase 2Recruiting

Regeneron AA Multicenter (Dupilumab)

Role: lead

NCT05549934Phase 2Completed

Ritlecitinib for Cicatricial Alopecia

Role: lead

NCT05076006Phase 2Completed

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

Role: lead

NCT02684097Phase 2Completed

A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

Role: lead

All 4 trials loaded